Joerg Herrmann MD
Professor of Medicine, Mayo Graduate School of Medicine, Rochester, MinnesotaDr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently, he is a Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He currently is the chair of the Scientific Committee of the International Cardio-Oncology Society and an associated editor of several journals including the European Heart Journal (EHJ), EHJ Open, Trends in Cardiovascular Medicine, International Journal of Cardiology, Frontiers in Cardiovascular Medicine, and Current Cardiology Reports. He is also a regular contributor to Braunwald's Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and the editor of the Cardio-Oncology Companion Book to Braunwald’s Heart Disease as well as the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Disclosures
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib. He also reports disclosures from Pfizer.
Recent Contributions to PracticeUpdate:
- ACC.15–Dr. Joerg Herrmann Reports In: Day 2
- ACC.15: No Clear Winner in PROMISE
- ACC.15: Interpreting the PROMISE Results
- ACC.15: PEGASUS-TIMI 54–Ticagrelor Improves Outcomes at Expense of Higher Bleeding Risk
- Temporal Trends in Revascularization Strategy and Outcomes in Left Main Coronary Artery Stenosis
- ACC.15—Late-Breaking Trial Recommendations From Joerg Herrmann
- Optimal Medical Therapy Improves Outcomes of PCI and CABG
- Pharmacoinvasive Strategy vs Primary PCI After Prolonged Delays
- Changes Over Time in Risk Profiles of Patients Who Undergo Coronary Artery Bypass Graft Surgery
- Effectiveness of Cath Lab–Only Eptifibatide Delivery in PCI Patients